HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Kazumi Kimura Selected Research

Tissue Plasminogen Activator (Alteplase)

1/2015The susceptibility vessel sign at the proximal M1: a strong predictor for poor outcome after intravenous thrombolysis.
12/2014THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial.
6/2014Thrombolytic therapy for stroke in patients with preexisting cognitive impairment.
1/2014Risk of intracerebral hemorrhage after thrombolysis in patients with asymptomatic hemorrhage on T2*.
1/2014The role of small vessel disease in re-exacerbation of stroke symptoms within 24 hours after tissue plasminogen activator infusion.
10/2013Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.
10/2013New appearance of extraischemic microbleeds on T2*-weighted magnetic resonance imaging 24 hours after tissue-type plasminogen activator administration.
9/2013[Diagnosis and treatment of acute ischemic stroke].
7/2013Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society.
4/2013NIHSS-time score easily predicts outcomes in rt-PA patients: the SAMURAI rt-PA registry.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Kazumi Kimura Research Topics

Disease

73Stroke (Strokes)
08/2015 - 09/2002
17Atrial Fibrillation
08/2015 - 01/2005
15Cerebral Hemorrhage
12/2015 - 01/2011
7Intracranial Hemorrhages (Intracranial Hemorrhage)
08/2015 - 09/2008
5Infection
12/2015 - 10/2011
4Hemorrhage
12/2015 - 09/2008
4Transient Ischemic Attack
08/2015 - 09/2002
4Hyperglycemia
05/2015 - 11/2009
4Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
07/2014 - 02/2013
4Heart Failure
03/2010 - 01/2009
3Hypertension (High Blood Pressure)
02/2015 - 04/2008
3Hematoma
01/2015 - 12/2012
3Cerebral Infarction
07/2014 - 01/2013
3Thrombosis (Thrombus)
02/2011 - 01/2009
2Malaria
12/2015 - 10/2013
2Kidney Diseases (Kidney Disease)
11/2015 - 05/2014
2Alzheimer Disease (Alzheimer's Disease)
04/2015 - 02/2015
2Body Weight (Weight, Body)
12/2014 - 11/2014
2Embolism (Embolus)
07/2014 - 08/2013
2Pulmonary Embolism
01/2009 - 09/2002
2Brain Infarction
11/2008 - 09/2002
2Heart Diseases (Heart Disease)
10/2008 - 06/2002
1Parkinson Disease (Parkinson's Disease)
09/2015
1Ischemia
08/2015
1Brain Injuries (Brain Injury)
05/2015
1Epilepsy (Aura)
05/2015
1Arteriosclerosis
05/2015
1Memory Disorders (Memory Loss)
04/2015
1Amyloid Plaque
02/2015
1Gliosis
02/2015
1Pathologic Constriction (Stenosis)
02/2015
1Atherosclerosis
01/2015
1Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
02/2014
1Blindness (Hysterical Blindness)
01/2013
1Optic Atrophy
09/2012
1Hyperammonemia
01/2012
1Hypothyroidism
01/2012
1Inflammation
01/2012
1Vasculitis (Vasculitides)
01/2012
1Hypoglycemia (Reactive Hypoglycemia)
01/2012
1Collagen Diseases (Collagen Disease)
01/2012
1Cerebral Malaria
10/2011
1Parasitemia
10/2011
1Thrombophilia
01/2011
1Heart Neoplasms
01/2011

Drug/Important Bio-Agent (IBA)

41Tissue Plasminogen Activator (Alteplase)FDA Link
01/2015 - 01/2004
16glucuronyl glucosamine glycan sulfate (Vessel)IBA
11/2015 - 06/2002
15Brain Natriuretic Peptide (Natrecor)FDA Link
12/2014 - 01/2009
9Glucose (Dextrose)FDA LinkGeneric
03/2014 - 09/2008
8Biological Markers (Surrogate Marker)IBA
05/2015 - 01/2009
5Warfarin (Coumadin)FDA LinkGeneric
12/2015 - 11/2011
5AnticoagulantsIBA
08/2015 - 08/2013
3Vitamin KFDA Link
08/2015 - 01/2015
3N(4)-oleylcytosine arabinosideIBA
01/2015 - 08/2013
3Fibrinolytic Agents (Antithrombotic Agents)IBA
01/2013 - 01/2004
2Amyloid (Amyloid Fibrils)IBA
04/2015 - 02/2015
2Blood Glucose (Blood Sugar)IBA
03/2015 - 08/2011
2Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
02/2015 - 11/2008
2Nicardipine (Dagan)FDA LinkGeneric
11/2014 - 12/2012
2Retinaldehyde (Retinal)IBA
01/2013 - 09/2012
2Hemoglobins (Hemoglobin)IBA
04/2012 - 10/2008
2fibrin fragment D (D-dimer)IBA
01/2011 - 01/2009
2FibrinIBA
01/2011 - 01/2009
2DobutamineFDA LinkGeneric
04/2003 - 02/2003
1Neutralizing AntibodiesIBA
12/2015
1InterferonsIBA
12/2015
1chenodeoxycholate sulfate conjugate (CDCS)IBA
12/2015
1Levodopa (L Dopa)FDA LinkGeneric
09/2015
1fluoro-jade CIBA
05/2015
1von Willebrand FactorIBA
05/2015
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
05/2015
1CalciumIBA
05/2015
1Peroxidase (Myeloperoxidase)IBA
05/2015
1Streptozocin (Streptozotocin)FDA Link
05/2015
1Valproic Acid (Valproate, Semisodium)FDA LinkGeneric
05/2015
1Unithiol (DMPS)IBA
03/2015
1tau Proteins (tau Protein)IBA
02/2015
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
02/2015
12'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
02/2015
1clopidogrel (Plavix)FDA Link
02/2015
1cilostazol (Pletal)FDA LinkGeneric
02/2015
1corrigendumIBA
01/2015
1CreatinineIBA
05/2014
1Interleukin-12 (IL 12)IBA
03/2014
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
10/2013
1AntigensIBA
10/2013
1Proteins (Proteins, Gene)IBA
10/2013
1OvalbuminIBA
10/2013
1MCOIBA
10/2013
1HormonesIBA
09/2013
1phenylmethylpyrazoloneIBA
02/2012
1Amyloid angiopathyIBA
01/2012
1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
01/2012
14- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA
01/2012
1flt3 ligand protein (flt3 ligand)IBA
10/2011

Therapy/Procedure

4Thrombolytic Therapy
06/2014 - 01/2005
1Transplantation (Transplant Recipients)
04/2015
1Stem Cell Transplantation
04/2015
1Long-Term Care
01/2015
1Renal Dialysis (Hemodialysis)
01/2013